BluntForceOptions
Nov 5, 10:16 PM
$VYGR Q3 2026 earnings & PL update.
Voyager just dropped their Q3 numbers, and the operational execution here is clinically tight. The bal sheet is derisked, IMO, cash burn is down, and the primary Q4 catalyst remains fully on track.
Here's a breakdown of the key milestones and PL updates from the PR:
• "Ended Q3 2026 with cash position of
$132 million, runway into Q2 2028".
• Voyager was highly disciplined with capital allocation, reducing R&D expenses down to
$24.4 million and G&A down to
$6.1 million for the Q.
• “VY7523 (anti-tau antibody): The last patient visit is complete, and Voyager continues to expect tau positron emission tomography (PET) imaging efficacy data in Q4 2026 from the multiple ascending dose (MAD) clinical trial in participants with Alzheimer’s disease (AD).”
• “VY1706 (tau silencing gene therapy): Patient screening continues in the United States for the clinical trial in adults with early AD, and, pending enrollment, Voyager expects patient dosing to begin in the next few months, initial acute safety data in the first quarter of 2027, and the potential to establish capsid platform validation with initial CSF tau biomarker-based data approximately one year after dosing begins.”
• “NBIB-‘223 (Friedreich’s ataxia gene therapy): Voyager’s partner, Neurocrine Biosciences, said that the program is expected to enter a Phase 1 clinical study in the coming months, with initial patient-level data anticipated in 2027.”
Upcoming institutional catalyst and presentation calendar:
• Nov 9: Guggenheim 3rd Annual Healthcare Innovation Conference.
• Nov 10: Stifel 2026 Healthcare Conference.
• Nov 16-19: 19th CTAD Conference.
• Dec 13-16: Antibody Engineering & Therapeutics US 2026 Conference.
With the broader market and biotech sector getting aggressively sold off, the current valuation, IMO, is a massive disconnect from the fundamental reality of this pipeline. I'm long the common equity and have continued aggressively adding to my position on this sector-wide weakness. This is a prime opportunity to scale into a derisked bal sheet at a washed-out valuation with a major clinical data readout looming right around the corner. The asymmetric risk/reward here is exactly what we look for. Just sharing my opinion and work here. Check everything yourself. NFA.
0 replies
